New research has recently been published that builds upon evidence from a previous trial investigating the potential of Sabinsa’s Curcumin C3 Reduct^® ingredient in oral care applications.

Read more ...

Dr. Kalyanam Nagabhushanam, President (R&D), Sabinsa Corporation presented, at the invitation of FDA, a seminar on December 10, 2020 to a group of US FDA scientists as part of the CDER Botanical Drug Seminar Series (BDSS).

Read more ...

Sabinsa ends the year with more good news about achievements. The Confederation of Indian Industry (CII) recognized the Sami-Sabinsa Group with two awards for IP property, and Sami-Sabinsa Founder and Chairman, Dr. Muhammed Majeed, was honored by the Indian Association for the Study of Traditional Asian Medicine (IASTAM). Additionally, the company has been granted five new U.S. patents, including strengthening IP protection on its flag-ship probiotic, LactoSpore^® with new applications, and additional patents for novel compositions.

Read more ...

Sabinsa’s proprietary formulation Macumax^® was shown to have vision health benefits in a clinical trial on subjects diagnosed with age-related macular degeneration (AMD). The study An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related Macular Degeneration authored by Muhammed Majeed, Shaheen Majeed and Kalyanam Nagabhushanam, was published in the Journal of Medicinal Food (ahead of print doi.org/10.1089/jmf.2020.0097).

Read more ...

Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group was honored with a lifetime achievement award in recognition of his exemplary services in the nutraceuticals and cosmeceuticals industry by ASSOCHAM (The Associated Chambers of Commerce and Industry of India). The award was presented as part of Ayush Mela, one of India’s largest exhibition and conference events related to Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy (AYUSH).

Read more ...

Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group has recently published the fourth book in a series on derivatives of Boswellia serrata.

Read more ...

Sabinsa, a pioneer in the nutraceutical and cosmeceutical industry, has provided documentation to appropriate government agencies in its continuing efforts to identify and remove adulterated vitamin C additives from the market, a practice to which Sabinsa alerted the industry earlier this year.

Read more ...

Sabinsa, a pioneer in nutraceutical and cosmeceutical industry, is offering glyphosate test results to customers, using a proprietary method for testing glyphosate developed by scientists at parent company Sami-Sabinsa. In October they began testing for residual herbicide in 20 nutraceutical ingredients as a routine practice, along with all other USP listed pesticides, and are widening the scope to all products the company sells. Spices must be below 7 ppm and herbs below 0.2 ppm.

Read more ...

Sabinsa, a pioneer in the nutraceutical and cosmeceutical industries, has expanded its large portfolio of intellectual property with a new patent granted in Mexico for the company’s Boswellia serrata ingredient Boswellin^® PS.

Read more ...

Sabinsa, a pioneer in nutraceutical and cosmeceutical industry, has strengthened its market position in Canada with the grant of three new patents. The company has also received an additional Natural Products Number (NPN) issued by Health Canada, bringing their total number of products with health claims in Canada to 37.

Read more ...